Paul W.A. Janssen

2.1k total citations · 1 hit paper
30 papers, 792 citations indexed

About

Paul W.A. Janssen is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Internal Medicine. According to data from OpenAlex, Paul W.A. Janssen has authored 30 papers receiving a total of 792 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Cardiology and Cardiovascular Medicine, 18 papers in Surgery and 7 papers in Internal Medicine. Recurrent topics in Paul W.A. Janssen's work include Antiplatelet Therapy and Cardiovascular Diseases (29 papers), Acute Myocardial Infarction Research (13 papers) and Atrial Fibrillation Management and Outcomes (11 papers). Paul W.A. Janssen is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (29 papers), Acute Myocardial Infarction Research (13 papers) and Atrial Fibrillation Management and Outcomes (11 papers). Paul W.A. Janssen collaborates with scholars based in Netherlands, United States and Belgium. Paul W.A. Janssen's co-authors include Jurriën M. ten Berg, Thomas O. Bergmeijer, Vera H.M. Deneer, Willem J.M. Dewilde, Johannes C. Kelder, Folkert W. Asselbergs, Arnoud W.J. van ‘t Hof, Jean‐Paul R. Herrman, Daniel M.F. Claassens and Anthonius de Boer and has published in prestigious journals such as New England Journal of Medicine, JAMA and Circulation.

In The Last Decade

Paul W.A. Janssen

27 papers receiving 774 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Genotype-Guided Strategy for Oral P2Y ₁₂ Inhibitors in Primary PCI

2019 378 citations Daniel M.F. Claassens, Gerrit J.A. Vos et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul W.A. Janssen Netherlands	14	693	354	202	77	75	30	792
Thomas O. Bergmeijer Netherlands	15	1.0k 1.5×	513 1.4×	280 1.4×	148 1.9×	84 1.1×	33	1.1k
Daniel M.F. Claassens Netherlands	8	442 0.6×	237 0.7×	118 0.6×	75 1.0×	67 0.9×	16	517
Willem J.M. Dewilde Netherlands	9	1.6k 2.2×	488 1.4×	456 2.3×	75 1.0×	69 0.9×	19	1.7k
Gerrit J.A. Vos Netherlands	6	381 0.5×	199 0.6×	99 0.5×	64 0.8×	63 0.8×	9	451
Renicus S. Hermanides Netherlands	11	647 0.9×	575 1.6×	146 0.7×	99 1.3×	60 0.8×	45	986
N. von Beckerath Germany	7	429 0.6×	221 0.6×	93 0.5×	148 1.9×	61 0.8×	8	541
Ilaria Sestini Italy	10	413 0.6×	254 0.7×	62 0.3×	126 1.6×	47 0.6×	14	653
Geneviève Le Calvez France	8	604 0.9×	271 0.8×	125 0.6×	105 1.4×	31 0.4×	14	905
Jeremiah P. Depta United States	18	558 0.8×	297 0.8×	85 0.4×	39 0.5×	23 0.3×	57	713
C. M. Hackeng Netherlands	15	702 1.0×	352 1.0×	199 1.0×	155 2.0×	21 0.3×	28	876

Countries citing papers authored by Paul W.A. Janssen

Since Specialization

Citations

This map shows the geographic impact of Paul W.A. Janssen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul W.A. Janssen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul W.A. Janssen more than expected).

Fields of papers citing papers by Paul W.A. Janssen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul W.A. Janssen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul W.A. Janssen. The network helps show where Paul W.A. Janssen may publish in the future.

Co-authorship network of co-authors of Paul W.A. Janssen

This figure shows the co-authorship network connecting the top 25 collaborators of Paul W.A. Janssen. A scholar is included among the top collaborators of Paul W.A. Janssen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul W.A. Janssen. Paul W.A. Janssen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sandner, Sigrid, Björn Redfors, Dominick J. Angiolillo, et al.. (2022). Association of Dual Antiplatelet Therapy With Ticagrelor With Vein Graft Failure After Coronary Artery Bypass Graft Surgery. JAMA. 328(6). 554–554. 46 indexed citations

Claassens, Daniel M.F., Thomas O. Bergmeijer, Gerrit J.A. Vos, et al.. (2021). Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype. Circulation Cardiovascular Interventions. 14(4). 17 indexed citations

Willemsen, Laura M., Paul W.A. Janssen, Johannes C. Kelder, et al.. (2021). Blood loss after coronary artery bypass by aspirin responsiveness assessed with preoperative VerifyNow aspirin testing. Research and Practice in Thrombosis and Haemostasis. 5(8). e12623–e12623. 5 indexed citations

Li, Ning, Anuradha Kalyanasundaram, Brian J. Hansen, et al.. (2021). B-PO04-013 PERIOSTIN AS A MARKER OF FIBROTIC SUBSTRATE FOR REENTRANT ATRIAL FIBRILLATION DRIVERS IN HUMAN HEARTS. Heart Rhythm. 18(8). S284–S285. 1 indexed citations

Bergmeijer, Thomas O., Gerrit J.A. Vos, Paul W.A. Janssen, et al.. (2020). Effect of CYP3A4*22 and PPAR-α Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention. Genes. 11(9). 1068–1068. 1 indexed citations

Claassens, Daniel M.F., Gerrit J.A. Vos, Thomas O. Bergmeijer, et al.. (2019). A Genotype-Guided Strategy for Oral P2Y ₁₂ Inhibitors in Primary PCI. New England Journal of Medicine. 381(17). 1621–1631. 378 indexed citations breakdown →

Willemsen, Laura M., Paul W.A. Janssen, C. M. Hackeng, et al.. (2019). A randomized, double-blind, placebo-controlled trial investigating the effect of ticagrelor on saphenous vein graft patency in patients undergoing coronary artery bypass grafting surgery—Rationale and design of the POPular CABG trial. American Heart Journal. 220. 237–245. 3 indexed citations

Godschalk, Thea C., Marieke E. Gimbel, Giovanni Amoroso, et al.. (2018). A clinical risk score to identify patients at high risk of very late stent thrombosis. Journal of Interventional Cardiology. 31(2). 159–169. 5 indexed citations

Janssen, Paul W.A., et al.. (2017). Does percutaneous coronary stent implantation increase platelet reactivity?. Blood Reviews. 31(5). 271–275. 5 indexed citations

10.

Bergmeijer, Thomas O., Paul W.A. Janssen, Thea C. Godschalk, et al.. (2017). Incidence and Causes for Early Ticagrelor Discontinuation: A “Real-World” Dutch Registry Experience. Cardiology. 138(3). 164–168. 23 indexed citations

11.

Dewilde, Willem J.M., Paul W.A. Janssen, Johannes C. Kelder, et al.. (2015). Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial. EuroIntervention. 11(4). 381–390. 21 indexed citations

12.

Janssen, Paul W.A., et al.. (2015). Antithrombotic therapy in the anticoagulated patient undergoing percutaneous coronary intervention with coronary stenting. Current Opinion in Cardiology. 30(4). 319–324.

13.

Heestermans, Antonius A.C.M., J. Wouter Jukema, Michiel Voskuil, et al.. (2015). Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older—rationale and design of the POPular AGE study. American Heart Journal. 170(5). 981–985.e1. 28 indexed citations

14.

Janssen, Paul W.A., Jurriën M. ten Berg, Frans L. Moll, et al.. (2015). The use of platelet reactivity testing in patients on antiplatelet therapy for prediction of bleeding events after cardiac surgery. Vascular Pharmacology. 77. 19–27. 11 indexed citations

15.

Fontana, Pierre, Willibald Hochholzer, Franz‐Josef Neumann, et al.. (2015). Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Thrombosis and Haemostasis. 115(4). 823–825. 25 indexed citations

16.

Janssen, Paul W.A., Jurriën M. ten Berg, & Christian M. Hackeng. (2014). The use of platelet function testing in PCI and CABG patients. Blood Reviews. 28(3). 109–121. 16 indexed citations

17.

Bergmeijer, Thomas O., Paul W.A. Janssen, Folkert W. Asselbergs, et al.. (2014). CYP2C19 genotype–guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. American Heart Journal. 168(1). 16–22.e1. 60 indexed citations

18.

Dewilde, Willem J.M., Paul W.A. Janssen, Freek W.A. Verheugt, et al.. (2014). Triple Therapy for Atrial Fibrillation and Percutaneous Coronary Intervention. Journal of the American College of Cardiology. 64(12). 1270–1280. 36 indexed citations

19.

Bergmeijer, Thomas O., et al.. (2013). Ticagrelor is frequently discontinued in a real world setting. European Heart Journal. 34(suppl 1). P4867–P4867. 2 indexed citations

20.

Janssen, Paul W.A. & Jurriën M. ten Berg. (2013). Platelet Function Testing and Tailored Antiplatelet Therapy. Journal of Cardiovascular Translational Research. 6(3). 316–328. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact